Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluticasone propionate + vitamin D is a combination of a synthetic glucocorticoid corticosteroid (fluticasone propionate) and a fat-soluble secosteroid (vitamin D, typically as cholecalciferol or ergocalciferol). Fluticasone propionate acts as an anti-inflammatory agent by binding to the glucocorticoid receptor, reducing inflammation in the airways or nasal passages. Vitamin D plays a role in calcium homeostasis and immune modulation. This combination has been studied for use in allergic rhinitis and asthma management; some studies suggest that adding vitamin D to standard intranasal or inhaled corticosteroid therapy may provide additional symptom relief for allergic rhinitis or improve regulatory effects on serum 25-hydroxyvitamin D levels in asthma patients[4][6][8]. However, this is not an approved fixed-dose pharmaceutical product but rather refers to concurrent administration of both agents. The mechanism involves anti-inflammatory action via glucocorticoid receptor agonism (fluticasone) and immunomodulatory effects through the nuclear hormone receptor family (vitamin D receptor).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluticasone propionate + vitamin d.